KATP Channel Opener Diazoxide Prevents Neurodegeneration: A New Mechanism of Action via Antioxidative Pathway Activation

dc.contributor.authorVirgili, Noemi
dc.contributor.authorMancera, Pilar
dc.contributor.authorWappenhans, Blanca
dc.contributor.authorSorrosal, Georgina
dc.contributor.authorBiber, Knut
dc.contributor.authorPugliese, Marco
dc.contributor.authorEspinosa Parrilla, Juan Francisco
dc.date.accessioned2021-03-16T10:59:01Z
dc.date.available2021-03-16T10:59:01Z
dc.date.issued2013-09-11
dc.date.updated2021-03-16T10:59:01Z
dc.description.abstractPharmacological modulation of ATP-sensitive potassium channels has become a promising new therapeutic approach for the treatment of neurodegenerative diseases due to their role in mitochondrial and cellular protection. For instance, diazoxide, a well-known ATP-sensitive potassium channel activator with high affinity for mitochondrial component of the channel has been proved to be effective in animal models for different diseases such as Alzheimer's disease, stroke or multiple sclerosis. Here, we analyzed the ability of diazoxide for protecting neurons front different neurotoxic insults in vitro and ex vivo. Results showed that diazoxide effectively protects NSC-34 motoneurons from glutamatergic, oxidative and inflammatory damage. Moreover, diazoxide decreased neuronal death in organotypic hippocampal slice cultures after exicitotoxicity and preserved myelin sheath in organotypic cerebellar cultures exposed to pro-inflammatory demyelinating damage. In addition, we demonstrated that one of the mechanisms of actions implied in the neuroprotective role of diazoxide is mediated by the activation of Nrf2 expression and nuclear translocation. Nrf2 expression was increased in NSC-34 neurons in vitro as well as in the spinal cord of experimental autoimmune encephalomyelitis animals orally administered with diazoxide. Thus, diazoxide is a neuroprotective agent against oxidative stress-induced damage and cellular dysfunction that can be beneficial for diseases such as multiple sclerosis.
dc.format.extent11 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec641209
dc.identifier.issn1932-6203
dc.identifier.pmid24040400
dc.identifier.urihttps://hdl.handle.net/2445/175179
dc.language.isoeng
dc.publisherPublic Library of Science (PLoS)
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0075189
dc.relation.ispartofPLoS One, 2013, vol. 8, num. 9, p. e75189
dc.relation.urihttps://doi.org/10.1371/journal.pone.0075189
dc.rightscc-by (c) Virgili, Noemi et al., 2013
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es
dc.sourceArticles publicats en revistes (Biomedicina)
dc.subject.classificationEsclerosi múltiple
dc.subject.classificationMalalties neurodegeneratives
dc.subject.classificationAntioxidants
dc.subject.otherMultiple sclerosis
dc.subject.otherNeurodegenerative Diseases
dc.subject.otherAntioxidants
dc.titleKATP Channel Opener Diazoxide Prevents Neurodegeneration: A New Mechanism of Action via Antioxidative Pathway Activation
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
641209.pdf
Mida:
9.59 MB
Format:
Adobe Portable Document Format